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SHORT COMMUNICATION
Serum interleukin 6 and C-reactive protein levels correlate with resistance
to IL-2 therapy and poor survival in melanoma patients
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Summary Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from
metastatic melanoma patients. Patients with elevated serum IL-6 (>20 pg ml-') and/or CRP (>10 mg `')
levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a
shorter median survival was also observed.
The prognosis of patients with metastatic melanoma remains
poor, with a median survival that does not exceed 6 months
(Koh, 1991). Most clinical trials using interleukin 2 in metas-
tatic melanoma have shown an average response rate of
about 15-25% (Dillman et al., 1993; Tartour et al., 1992).
Therefore, since the overall response rate is low and treat-
ment is associated with drug toxicity, many attempts have
been made to predict clinical response. Up until now, only
HLA phenotype has been correlated with response to IL-2 in
melanoma (Marincola et al., 1992). In renal cell carcinoma,
patients with detectable serum interleukin 6 (IL-6) and/or
CRP > 50 mg 1' before starting IL-2 treatment have a poor
response to IL-2 (Blay et al., 1992). Renal cell carcinoma and
melanoma share some common features, such as IL-6 secre-
tion and expression of membrane IL-6 receptor by tumour
cells and the modulation of tumour cell proliferation by IL-6
(Miki et al., 1989; Lee et al., 1992; Lu et al., 1992). This
prompted us to study serum IL-6 and CRP concentrations in
melanoma patients prior to IL-2 therapy, in order to evaluate
their predictive value for clinical outcome.
Materials and methods
Patients
A total of 30 patients with histologically proven metastatic
melanoma, stage IV according to the American Join Com-
mission on Cancer (AJCC) classification, were included in
immunotherapy protocols with IL-2 aftf, obtaining their
written informed consent. No other anti-cancer agents were
given during the 3 weeks before IL-2 therapy. Patient charac-
teristics are shown in Table I.
According to the AJCC (Beahrs et al., 1988) and studies
by Markowitz et al. (1991) and Balch et al. (1983), these
stage IV melanomas were divided into two prognostic
groups: Mla, poor prognosis with visceral metastases; Mlb,
intermediate prognosis with metastases in skin, subcutaneous
tissue or lymph nodes beyond the regional lymph nodes.
Disease-free interval was measured as the time between
definitive treatment of the primary disease to diagnosis of
relapse.
A tumour response was considered complete (CR) if all
measurable disease disappeared for more than 1 month. A
partial response (PR) was defined as a 50% decrease in the
size of the longest perpendicular cross-sectional diameter of
all lesions that lasted at least 1 month without appearance of
new tumour.
Assays
Serum samples were obtained from all patients during the
first course of IL-2 on day 0 (before starting treatment) and
were frozen at -20°C until the assay.
Human IL-6 was assayed using ELISA kits purchased
from Immunotech (Marseille, France).
CRP was assayed by a rate immunonephelometric techni-
que on an Erratum protein system analyser (Automatic Beck-
man, Beckman Instrument).
The 95th percentiles for serum CRP and IL-6 levels in
normal individuals in our laboratory were 10 mg 1` and
20 pg ml-' respectively.
Statistical analysis
Data were compared using a two-tailed Fisher exact test.
Survival was calculated from the start of IL-2-based therapy
to the date of death. Patients who had not died were cen-
sored at the date of last follow-up. Survival parameters were
estimated using the Kaplan-Meier method and compared
using a log-rank test. Statistical significance was defined as
P<0.05.
Results
Pretreatment serum IL-6 and CRP in melanoma patients
High serum IL-6 and CRP levels prior to IL-2 therapy were
found in respectively 26.6% (8/30) and 46% (13/28) of
metastatic melanoma patients (Figure la and b). Elevated
serum IL-6 and CRP concentrations were equally distributed
among patients treated with the various IL-2 regimens (data
not shown). A trend towards a correlation between IL-6 and
CRP concentrations was observed, but this was not statis-
tically signiticant (P> 0.05).
Correlation between pretreatment serum IL-6 and CRP
concentrations and clinical response
An association between both serum CRP and serum IL-6
levels and clinical response was observed. Only 1 out of 13
patients with CRP > 10 mg 1I responded to IL-2 therapy,
whereas 6 out of 15 patients with CRP <10 mgI
1 achieved
a clinical response (Figure la). Similarly, none of the 8
patients with elevated IL-6 levels responded to IL-2 (Figure
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Table I Patient characteristics
Characteristics No. ofpatients
Age (years)
Median 46
Range 20-69
Male:female 1.5
Disease-free interval (months) 30
Median 03108
Range
Metastases
Mla 24
Mlb 6
Schedules of IL-2 regimens (per cycle)
1. IL-2: continuous i.v. infusion of 18
20 x 106 IU m-2 24 h 'on days 1-5,
15-18 and 29-31
2. Cisplatin: lOOmgm-2 24h-' on day 1; and 5
IL-2: 18 x 106 IU m-2 24h-1 on days 4-7
and 18-22
3. As 2 plus IFN-a2a: 9 x 106 IU 24h-' three 7
times a week associated with IL-2
Response
Partial (PR) 6
Complete (CR) 1
Stable (SD) and progressive disease (PD) 23
Mla, visceral metastases; Mlb, metastases in skin, subcutaneous
tissue, or lymph node beyond the regional lymph node.
Table II Relationship between serum IL-6 and CRP levels before
IL-2 therapy and prognosis and survival
Prognosis 12 month survival after
Poor Intermediate onset IL-2 therapy (%)
IL-6>20pgml-' 8 0 0
IL-6<20pgml-' 16 6 P*=0.15 22.5 P**=0.01
CRP> 10mg l` 10 3 13
CRP<lOmgl-' 12 3 NS 25 P=0.09
IL-6>20pgml-' and/or 13 3 10
CRP>lOmgl'I
IL-6<20pgml-' and 9 3 NS 30 P=0.07
CRP<lOmgl
*Fisher exact test, **log-rank test. NS, not significant.
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Ib). This univariate analysis was unable to predict clinical
response with statistical significance, probably because of the
small number of patients. However, when serum IL-6 and
CRP levels were combined, a clear correlation between these
markers and clinical response was demonstrated (P = 0.02)
(Figure 1c). In fact, only one clinical response was observed
in the group of 16 melanoma patients with IL-6
>20 pgml-' and/or CRP > 10mglI'. In contrast, 50% of
clinical responses were recorded in the group of 12 patients
with normal serum IL-6 and CRP values (Figure 1c).
Correlation between prognosticfactors and serum IL-6 and
CRP concentrations
According to previous studies (Balch et al., 1983; Markowitz
et al., 1991), these stage IV melanoma patients were divided
into two prognostic groups: poor and intermediate prognosis.
Although all patients with serum IL-6 levels >20 pg ml'
belonged to the poor prognosis group, no clear correlation
was demonstrated between serum IL-6 and CRP concentra-
tions and the clinically defined prognostic groups (Table II).
Finally, survival analysis revealed a clear correlation between
a high serum IL-6 level and fatal outcome (Table II). In fact,
patients with high serum IL-6 levels had a median survival of
3 months compared with 9 months in patients with low
serum IL-6 levels (P = 0.01).
Discussion
This study identified a group of melanoma patients with
elevated serum IL-6 and/or CRP levels, which were
associated with a poor clinical response to IL-2 therapy. In
contrast, a 50% clinical response rate was observed in
patients with normal serum IL-6 and CRP levels, whereas a
clinical response of about 22% was recorded in the overall
population of melanoma patients treated. No response to
IL-2 therapy was recorded in patients with elevated serum
IL-6 levels. The type of IL-2 regimen did not seem to
influence the value of IL-6 and CRP as prognostic factors, as
the clinical response was not significantly different between
the various IL-2 regimens and the distribution of serum IL-6
and CRP concentrations seemed to be homogeneous between
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Figure 1 Relationship between serum CRP and IL-6 levels before IL-2 therapy and clinical response. Responders (-) and
non-responders (0) to IL-2 therapy were compared with regard to normal (<1O mg ml-') or pathological (>1Omg -') serum
CRP (a), normal (<20 pg ml-') or elevated (>20 pgml-') serum IL-6 concentration (b), and to combined data, i.e. normal serum
CRP and IL-6 levels vs elevated serum IL-6 and/or CRP levels (c). Statistical analyses were performed with the Fisher exact test.
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patients treated with these different protocols (data not
shown).
These results are in accordance with previous studies
indicating a correlation between serum CRP and IL-6 levels
and clinical response to IL-2 therapy in patients with renal
cell carcinoma (Blay et al., 1992) and colorectal carcinoma
(Broom et al., 1992). Blay et al. found a good correlation
between serum IL-6 and CRP levels which was less marked
in this study.
We then wondered whether this poor IL-2 responder group
corresponded to clinical prognostic groups. Patients with
elevated serum IL-6 and/or CRP levels were not over-
represented in the poor prognosis group with statistical
significance. No relationship between serum IL-6 or CRP
levels and disease-free interval, site or number of metastases
was demonstrated (data not shown).
Patients with elevated serum IL-6 levels had a shorter
survival than patients with low serum IL-6 levels. This is
similar to the results reported by Blay et al. (1992), who
found an association between elevated serum IL-6 levels and
decreased survival in renal cell carcinoma.
The action of IL-6 on the immune system is complex, and
both beneficial and adverse effects have been reported. IL-6
enhances the cytotoxic activity of NK cells (Luger et al.,
1989), and an anti-tumour effect of recombinant IL-6 has
been reported in mice (Mule et al., 1990). When transplanted
in mice, a lung adenocarcinoma transfected with a cDNA
coding for IL-6 lost its tumorigenicity and induced an
effective immune response (Porgador et al., 1992). On the
other hand, high IL-6 concentrations inhibit T-cell pro-
liferative responses and tumour necrosis factor a (TNF-m)
synthesis (Aderka et al., 1989; Zhou et al., 1991).
Lu et al. (1992) showed that the growth of melanoma cells
obtained from early-stage (metastically incompetent) primary
lesions is inhibited by IL-6. This growth-inhibitory effect was
lost in the more advanced stage (metastatically competent)
derived cell lines, which also exhibited an increase in resis-
tance to other inhibitory factors such as IL-113, TNF-a and
transforming growth factor P (TGF-P) (Lu et al., 1992).
These resistance phenomena were often associated with spon-
taneous IL-6 secretion by these advanced-stage cell lines (Lu
et al., 1993). Therefore, this multicytokine resistance pheno-
type may explain the failure of IL-2 therapy in such patients,
if IL-2 acts by inducing selective cytokines or inhibitory
factors.
In conclusion, our study suggests that high serum IL-6
and/or CRP levels could constitute a prognostic factor to
stratify IL-2-treated melanoma patients.
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